Economic news

Abu Dhabi's ADNOC to Buy German Chemicals Company Covestro for $18B

BERLIN, Oct 1 (Reuters) - Abu Dhabi state oil giant ADNOC said on Tuesday that it has agreed to buy German chemicals producer Covestro for 15.9 billion euros ($18 billion) including debt, sending Covestro shares up 4% in early trade.

The deal represents one of the biggest foreign takeovers by a Gulf state as Abu Dhabi and other countries in the region seek to reduce their economies' heavy dependence on oil in the face of the global energy transition.

It follows protracted negotiations between the two companies and will see ADNOC pay 62 euros per Covestro share, equal to 14.7 billion euros including about 3 billion euros in debt.

Adnoc added it would also buy 1.17 billion euros worth of new shares in Covestro, a former Bayer unit, from a capital increase to improve funding of the takeover target.

The deal marks a cornerstone for ADNOC's plans to grow its petrochemicals business along with gas and renewable energy.

ADNOC has also been in talks with Austria's OMV for more than a year to merge their petrochemical joint ventures Borealis and Borouge. ADNOC took a 24.9% stake in OMV from Abu Dhabi sovereign fund Mubadala in February.

Covestro, which makes plastics and chemicals for the automotive, construction and engineering sectors, was created in 2015 after being spun off from Bayer. It opened its books to ADNOC in June - a year after ADNOC's initial interest was reported.

Covestro reported a net loss of 72 million euros in the first six months of the year, compared with 46 million euros profit in the previous year.

The agreement illustrates an increase in dealmaking between the Middle East and Europe, as Gulf investors are drawn to company valuations that lag those in the United States, an easier regulatory backdrop for buyers from the region, and where investment needs make them more welcome, advisers and analysts have told Reuters.

It is the Middle East's second biggest acquisition after Israel's Teva Pharmaceuticals move to buy Allergan's generic drugs business for around $40 billion in 2015, according to Dealogic data.

($1 = 0.8990 euros)

Reporting by Ludwig Burger Additional reporting by Friederike Heine Editing by David Goodman and Emelia Sithole-Matarise

Source: Reuters


To leave a comment you must or Join us


More news


Back to economic news list

By visiting our website and services, you agree to the conditions of use of cookies. Learn more
I agree